Transparency of smart beta ETFs a concern
Smart beta exchange traded funds (ETF) still lack appropriate levels of transparency with a strong majority of professional users of the funds expressing concerns over the difficulty of assessing risks within the funds.
However, this concern has not dampened appetite for smart beta ETFs with use expected to increase according to a survey of public and private European asset managers conducted by European fund manager Amundi and EDHEC-Risk Institute.
The survey covered 222 investment decision makers at the chief executive, chief investment officer, asset allocation and portfolio management levels in institutional and private wealth managers in 27 European countries.
According to a report on the survey, which was released yesterday, 88 per cent of respondents stated that smart beta indices required full transparency on methodology and risk analytics.
The report stated transparency offered protection against conflicts of interests and would improve the ‘informational efficiency' of the indexing industry but was lagging within the smart beta ETF sector.
"While transparency is important for market indices, it is all the more so for smart beta indices. Unfortunately, these indices' low level of transparency, which is routinely justified by the use of proprietary models, makes the evaluation of risks difficult," the report stated.
However, it seems this has not put off investment managers with the report also stating that of those who use smart beta strategies 49 per cent use ETFs or ETF-like products to invest in smart beta. At the same time smart beta ETFs or ETF like products represented a third of the total amount invested in smart beta by survey respondents.
AUTHOR
Jason Spits
Recommended for you
Global X has painted a worrying picture for active ETFs in Australia, with investor adoption proving uneven and the popularity of its low-cost index counterparts only growing stronger.
Australian equity ETFs attracted record inflows of $3.2 billion in 1Q25, while heightened volatility led to a decline in flows for global equity ETFs, according to Vanguard.
The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under management, quarterly flows show.
GQG Partners has revealed its quarterly flows for the first three months of 2025 were up 5.8 per cent, after a difficult final quarter of 2024 as a result of institutional redemptions.
